Gossamer Bio and Chiesi Group enter into international collaboration to commercialise Seralutinib
James Spargo | May 7, 2024 | News story | Research and Development | Chiesi, Chronic Diseases, Gossamer Bio, PAH, PH-ILD, collaboration
US-based clinical stage biopharma company Gossamer Bio and Italian research-focused biopharma group Chiesi Farmaceutici have entered into an international agreement to develop and commercialise seralutinib.
Most current PAH treatments are vasodilators, meaning they do not impact the progressive nature of the disease – seralutinib is an inhaled PDGFRα/β, CSF1R and c-KIT inhibitor delivered via dry powder inhaler with the aim to treat pulmonary hypertension (PH). This collaboration will assess its use in pulmonary arterial hypertension (PAH), and PH associated with interstitial lung disease (PH-ILD). Gossamer’s phase 3 PROSERA study was initiated in 2023 after the positive use of seralutinib’s in PAH treatment in the phase 2 TORREY study. Gossamer and Chiesi plan to begin a global phase 3 registrational study into seralutinib’s use for PH-ILD in mid-2025.
As part of the agreement, Gossamer will receive a $160m development reimbursement payment, and be eligible to receive up to $146m in regulatory and $180m in sales milestones.
“This partnership with Chiesi allows us to meaningfully deepen and rapidly accelerate our investment in seralutinib as a potential treatment for PAH, PH-ILD and other indications of high unmet medical need,” said Faheem Hasnain, co-founder, chairman and CEO of Gossamer. “We are particularly thrilled that this collaboration enables seralutinib to move directly into a phase 3 trial in PH-ILD, an indication with a paucity of available treatments, and a disease which we believe seralutinib is specifically designed to address.”
“Seralutinib is a potential paradigm-shifting therapy in PAH and PH-ILD, and we could not be more excited to partner with Gossamer to develop and bring this therapy to patients world-wide,” said Giuseppe Accogli, Group CEO of Chiesi. “Gossamer shares Chiesi’s commitment to using innovation to promote the health and well-being of people around the world and we are proud to add this collaboration as a key pillar to our next phase of growth.”
James Spargo
Related Content
EVerZom enters research and licensing agreement with GENFIT
EVerZom, a French biotech company developing exosome-based therapies for regenerative medicine, has entered into a …
Custom Pharmaceuticals launches new company for drug product development
Customs Pharmaceuticals, a full-service contract development and manufacturing organisation (CDMO), has launched Centrix Pharma Solutions, …
Chiesi expands La Chaussée-Saint-Victor site to manufacture next-gen inhalers
Chiesi, a biopharma group focused on treating respiratory diseases, has inaugurated an expansion of its …
